🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT06894329
Recruiting Observational

A Study for the PanCystPro Assay in the Management of Pancreatic Cystic Lesions

NCT06894329 · tracked via the Priya Life Science USA tracker
Sponsor
Amplified Sciences Inc
Phase
Observational
Started
2026-02-17
Last updated
2026-03-16

Condition(s) studied

Pancreatic Cystic Lesions

Study summary

The purpose of this research is to learn if the PanCystPro assay can help doctors in making decisions about treatment and monitoring of pancreatic cysts. The PanCystPro test measures glucose, carcinoembryonic antigen (CEA), and gastricsin biomarkers on fluid obtained from a pancreatic cyst. The test reports if the cyst fluid should be considered "Non-mucinous" or "Mucinous". Mucinous pancreatic cysts are more likely to progress to cancer while non-mucinous cysts seldom progress to cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Patients 18 years of age or older * Cross sectional imaging studies demonstrating a pancreatic cyst at least 12 mm in size where fluid sampling can aid in patient's management * Written informed consent. * The patient will be undergoing EUS with anticipated FNA extraction as part of standard patient care. Exclusion Criteria: * Patients diagnosed with pancreatic cancer. * Pregnant or lactating females. * Patients with contraindications to moderate or deep procedural sedation (necessary for the conduct of the endoscopic ultrasound) like major cardiorespiratory illness. * Patients with contraindications to FNA of a pancreatic cyst like being on blood thinners.

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Indiana University Indianapolis Indiana Recruiting
Beth Israel Deaconess Medical Center Boston Massachusetts Recruiting
Rutgers Health New Brunswick New Jersey Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06894329 on ClinicalTrials.gov ↗ ← All trials in the USA